Patrick Machado
CIK 1311210 · Chief Business Officer and CFO · last filed 2026-06-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$10.40M
Companies
16
Total Filings
137
Lifetime Open-Market Net
$27.09M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XENE | Director | 2,645 | $52.10 | $137.8K | $0 | 7 | 2026-06-03 |
| Adverum Biotechnologies, Inc. (ADVM) Delisted | Director | 0 | $4.36 | $0 | $214.4K | 15 | 2025-12-10 |
| ALMS | Director | 7,064 | $24.15 | $170.6K | $0 | 3 | 2025-08-01 |
| RCUS | Director | 38,600 | $23.80 | $918.7K | $0 | 7 | 2025-06-12 |
| ACELYRIN, Inc. (SLRN) Delisted | Director | 14,675 | $2.27 | $33.3K | $0 | 3 | 2024-06-11 |
| CHIMERIX INC (CMRX) Delisted | Director | 10,000 | $8.54 | $85.4K | $70.8K | 10 | 2023-06-12 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | — | $76.01 | — | $0 | 4 | 2022-08-17 |
| Principia Biopharma Inc. (PRNB) Delisted | Director | — | — | — | $0 | 3 | 2020-09-28 |
| Urovant Sciences Ltd. (UROV) Delisted | 10%+ Owner | 22,860,013 | $16.24 | $371.25M | $38.75M | 9 | 2019-06-19 |
| Myovant Sciences Ltd. (MYOV) Delisted | 10%+ Owner | 40,765,599 | $26.98 | $1.10B | $42.50M | 2 | 2019-06-06 |
| SCYX | Director | 60,000 | $4.23 | $253.8K | $165.4K | 7 | 2019-01-04 |
| ENDOCYTE INC (ECYT) Delisted | Director | 0 | — | — | $0 | 3 | 2018-12-21 |
| ABUS | 10%+ Owner | — | $4.26 | — | $0 | 2 | 2018-01-16 |
| ROCKET PHARMACEUTICALS, INC. (ITEK) Delisted | Director | — | — | — | $0 | 2 | 2017-06-21 |
| MEDIVATION, INC. (MDVN) Delisted | Director | 107,985 | — | — | -$54.43M | 52 | 2016-06-23 |
| MDV | Sr. Vice President and CFO | 486,123 | $18.35 | $8.92M | -$178.0K | 1 | 2007-03-20 |
Recent Filings · Page 2 of 14
137 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-11 | ACELYRIN, Inc. (SLRN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | RCUS | Grant (A) | +8,400 | $0 | EDGAR |
| 2024-06-05 | XENE | Grant (A) | — | $0 | EDGAR |
| 2023-10-06 | ACELYRIN, Inc. (SLRN) Delisted | Other (J) | +14,675 | $0 | EDGAR |
| 2023-06-16 | RCUS | Grant (A) | +6,800 | $0 | EDGAR |
| 2023-06-13 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-12 | CHIMERIX INC (CMRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-02 | XENE | Grant (A) | — | $0 | EDGAR |
| 2023-05-11 | ACELYRIN, Inc. (SLRN) Delisted | Other (J) | — | $0 | EDGAR |
| 2023-05-04 | — | Grant (A) | — | $0 |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.